Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

hn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. Additional programs include the clinical development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis; and CCX354, a CCR1 antagonist currently in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid a
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014 /PRNewswire/ ... acquired enzastaurin, a late-stage oncology drug, from Eli ... rights to develop, manufacture and commercialize enzastaurin globally, ... rights, data, and information. Lilly ... in Phase 2 and Phase 3 clinical trials ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
(Date:9/16/2014)... , Sept. 16, 2014   HemCon Medical ... of TriStar Wellness Solutions(R), Inc. (OTCQB: ... advanced medical products, announced today that the revenue ... by 39 percent, and microdispersed oxidized cellulose raw ... 2014.  Overall, TWSI expects third quarter revenues to ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 2HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 4
... April 26 Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... treatment of cancer, today announced that it will host a conference call ... Wednesday, May 5, 2010 , at 8:30 AM ET . , ... To participate in the conference ...
... , April 26 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing significant products primarily for the respiratory and ... call at 8:00 AM ET on Tuesday, ... the quarter ended March 31, 2010 .  Management will ...
Cached Medicine Technology:Micromet to Report First Quarter 2010 Financial Results on May 5 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3
(Date:9/17/2014)... Tampa, FL (PRWEB) September 17, 2014 Tina ... ), is finishing up her chemotherapy but not her fight ... up for the Komen Florida Suncoast “Race for the Cure” ... “I registered for the Komen Race for the Cure because ... breast cancer,” Griffin said. , As part of her efforts, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Four ... eighth annual Wailea Tennis Fantasy Camp on ... Maui’s prestigious Wailea Tennis Club, with three-time grand slam ... returning to Wailea, Maui for her fifth year. , ... match play with Davenport, recently inducted into the International ...
(Date:9/17/2014)... September 17, 2014 A raucous childhood ... come together to form author Nancy Chovancek’s laughter-filled new ... is a collection of short stories that prove the ... fun. With a positive message of empowerment and resilience, ... is a proven author with two books under her ...
(Date:9/17/2014)... This September 18-20, 22 participating developmentally-disabled athletes ... three stage outdoor sporting event in non-profit World T.E.A.M. ... , Hosted at The Center for Discovery ... five participating teams coached by able-bodied athletes. For each ... provide expert guidance as well as technical assistance. Like ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Lee ... settlement industry, will be appearing on The Balancing Act® ... two September episodes. , The segment will premiere on ... on 'The Balancing Act® airing on Lifetime Television®' with ... of Asset Funding Corp. for over a decade and ...
Breaking Medicine News(10 mins):Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... Polyp Detection by Thirteen Percent, SAN DIEGO, ... in San Diego (DDW 2008), world-renowned gastroenterologist,Jerome D. ... which evaluated the efficacy of the Third Eye(TM) ... physicians to visualize,abnormalities in the colon., The ...
... near Mosul in 2003 , , WEDNESDAY, May 21 (HealthDay News) ... near Mosul, Iraq, in 2003 returned home with a debilitating ... , But doctors were only able to diagnose the condition, ... to reliably identify the problem, said the authors of a ...
... (Amex: QGP, QGP.WSA, QGP.WSB) ( http://www.QuantumMD.com ) ... plan. The Company,increased its employment base by 23% since ... ft. to 10,600 sq. ft., and has moved a,branch ... Doral (west,Miami), Florida., Susan Darby Guillama, Executive Vice ...
... MINNEAPOLIS, May 21 ACM today announced a ... development efforts on,providing next generation technology and services ... of healthcare today: commercial plans and,payers, and federal ... Development Gary Loeber has been,named EVP/General Manager for ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
... Calif., May 21 LUMEDX Corporation, a ... information systems,(CVIS), introduces software to manage data ... The Anticoagulation Module empowers clinicians,by making critical ... safety., For more information -- including ...
Cached Medicine News:Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Some Iraq War Vets Suffer Breathing Problems 2Health News:Some Iraq War Vets Suffer Breathing Problems 3Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
... performance technologies - Quantum™ LEAP® balloon ... - unite in the Quantum™ Maverick® ... dilatation force balloon with exceptional deliverability. ... Maverick® shaft technology improves trackability and ...
... Libert Coronary Stent System ... of lesion access and ... a low crossing profile, ... catheter, the performance of ...
Medicine Products: